Utility of Versican and Hyaluronan Measurement in Induced Sputum as Biomarkers of Asthma

Associated Scientists to Help Minimize Allergies

Status and phase: Completed; Phase 4

Conditions: Allergic Asthma

Treatments: Drug: Inhaled corticosteroid (fluticasone)

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00980707

AI-005 versican

Details and patient eligibility

About

The purpose of this study is to determine the role of versican and hyaluronan measurements in induced sputum as biomarkers of asthma. Enroll 10 subjects with mild persistent asthma who are not receiving treatment with a controller therapy.

Full description

We will compare spirometry, eNO and sputum measurements of versican and hyaluronan before and after treatment with fluticasone 220 ug/bid.

Enrollment: 10 patients

Sex: All

Ages: 18 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Allergic asthma defined as a positive methacholine challenge

Exclusion criteria

• Non-atopic patients

Trial design

Primary purpose: Diagnostic

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

10 participants in 1 patient group

inhaled corticosteroid

Experimental group

Description:

All asthmatics will start inhaled corticosteroids.

Treatment:

Drug: Inhaled corticosteroid (fluticasone)